Sensus Healthcare, Inc. ( (SRTS) ) has released its Q2 earnings. Here is a breakdown of the information Sensus Healthcare, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for skin conditions, primarily operating in the healthcare sector with a focus on superficial radiotherapy (SRT) technology. In its second quarter of 2025, Sensus Healthcare reported revenues of $7.3 million, a decrease from the previous year’s $9.2 million. The company shipped 19 SRT systems, including international shipments, and saw a 27% increase in FDA treatment volume compared to the first quarter. Despite these operational achievements, the company faced a net loss of $1.0 million, attributed to lower sales and increased costs. Sensus Healthcare also announced strategic partnerships and certifications aimed at expanding its market presence and enhancing its product offerings. Looking ahead, the company anticipates favorable impacts from proposed changes in reimbursement policies, which could boost the adoption of its SRT technology starting in 2026.